Download PDF
Clin Colon Rectal Surg 2024; 37(03): 146-156
DOI: 10.1055/s-0043-1770383
Review Article

Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes

Charles M. Bowen
1   Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
,
Krishna M. Sinha
1   Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
,
Eduardo Vilar
1   Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas
› Author Affiliations Funding E.V. has a consulting or advisory role with Janssen Research and Development and Recursion Pharma. He has received research support from Janssen Research and Development.
› Further Information
    Permissions and Reprints

Abstract

The coming of age for cancer treatment has experienced exponential growth in the last decade with the addition of immunotherapy as the fourth pillar to the fundamentals of cancer treatment—chemotherapy, surgery, and radiation—taking oncology to an astounding new frontier. In this time, rapid developments in computational biology coupled with immunology have led to the exploration of priming the host immune system through vaccination to prevent and treat certain subsets of cancer such as melanoma and hereditary colorectal cancer. By targeting the immune system through tumor-specific antigens—namely, neoantigens (neoAgs)—the future of cancer prevention may lie within arm's reach by employing neoAg vaccines as an immune-preventive modality for hereditary cancer syndromes like Lynch syndrome. In this review, we discuss the history, current trends, utilization, and future direction of neoAg-based vaccines in the setting of hereditary colorectal cancer.

Keywords

neoantigen - Lynch syndrome - cancer vaccine - cancer prevention - hereditary colorectal cancer


Publication History

Article published online:
31 July 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 2021; 18 (04) 215-229
    Google Scholar
  • 2 Yarchoan M, Johnson III BA, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer 2017; 17 (04) 209-222
    Google Scholar
  • 3 Finn OJ. The dawn of vaccines for cancer prevention. Nat Rev Immunol 2018; 18 (03) 183-194
    Google Scholar
  • 4 Cafri G, Gartner JJ, Zaks T. et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest 2020; 130 (11) 5976-5988
    Google Scholar
  • 5 Ott PA, Hu Z, Keskin DB. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017; 547 (7662): 217-221
    Google Scholar
  • 6 Keskin DB, Anandappa AJ, Sun J. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 2019; 565 (7738): 234-239
    Google Scholar
  • 7 Sahin U, Türeci Ö. Personalized vaccines for cancer immunotherapy. Science 2018; 359 (6382): 1355-1360
    Google Scholar
  • 8 Hollingsworth RE, Jansen K. Turning the corner on therapeutic cancer vaccines. NPJ Vaccines 2019; 4: 7
    Google Scholar
  • 9 Kopetz S. et al. SO-11 KISIMA-01 trial: Safety, tolerability and immunogenicity of ATP128 with or without ezabenlimab (BI 754091) in patients with stage IV colorectal cancer – preliminary results from a phase 1b study. Ann Oncol 2021; 32: S206-S207
    Google Scholar
  • 10 Gubin MM, Artyomov MN, Mardis ER, Schreiber RD. Tumor neoantigens: building a framework for personalized cancer immunotherapy. J Clin Invest 2015; 125 (09) 3413-3421
    Google Scholar
  • 11 Robbins PF, Lu YC, El-Gamil M. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013; 19 (06) 747-752
    Google Scholar
  • 12 Gebert J, Gelincik O, Oezcan-Wahlbrink M. et al. Recurrent frameshift neoantigen vaccine elicits protective immunity with reduced tumor burden and improved overall survival in a Lynch syndrome mouse model. Gastroenterology 2021; 161 (04) 1288-1302.e13
    Google Scholar
  • 13 Kloor M, Reuschenbach M, Pauligk C. et al. A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial. Clin Cancer Res 2020; 26 (17) 4503-4510
    Google Scholar
  • 14 Ott PA, Hu-Lieskovan S, Chmielowski B. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 2020; 183 (02) 347-362.e24
    Google Scholar
  • 15 Martin SD, Brown SD, Wick DA. et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One 2016; 11 (05) e0155189
    Google Scholar
  • 16 Hilf N, Kuttruff-Coqui S, Frenzel K. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 2019; 565 (7738): 240-245
    Google Scholar
  • 17 Kimura T, McKolanis JR, Dzubinski LA. et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila) 2013; 6 (01) 18-26
    Google Scholar
  • 18 Gatti-Mays ME, Redman JM, Donahue RN. et al. A phase I trial using a multitargeted recombinant adenovirus 5 (CEA/MUC1/Brachyury)-based immunotherapy vaccine regimen in patients with advanced cancer. Oncologist 2020; 25 (06) 479-e899
    Google Scholar
  • 19 Gabitzsch ES, Tsang KY, Palena C. et al. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic. Oncotarget 2015; 6 (31) 31344-31359
    Google Scholar
  • 20 Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: tumor-associated antigens vs neoantigens. World J Gastroenterol 2018; 24 (48) 5418-5432
    Google Scholar
  • 21 Lesterhuis WJ, De Vries IJ, Schreibelt G. et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res 2010; 30 (12) 5091-5097
    Google Scholar
  • 22 Lesterhuis WJ, de Vries IJ, Schuurhuis DH. et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Ann Oncol 2006; 17 (06) 974-980
    Google Scholar
  • 23 Pedersen SR, Sørensen MR, Buus S, Christensen JP, Thomsen AR. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J Immunol 2013; 191 (07) 3955-3967
    Google Scholar
  • 24 Overwijk WW. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol 2017; 47: 103-109
    Google Scholar
  • 25 Budhu S, Loike JD, Pandolfi A. et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med 2010; 207 (01) 223-235
    Google Scholar
  • 26 Parkhurst MR, Yang JC, Langan RC. et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011; 19 (03) 620-626
    Google Scholar
  • 27 Bommi PV, Bowen CM, Reyes-Uribe L. et al. The transcriptomic landscape of mismatch repair-deficient intestinal stem cells. Cancer Res 2021; 81 (10) 2760-2773
    Google Scholar
  • 28 Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507
    Google Scholar
  • 29 Cerretelli G, Ager A, Arends MJ, Frayling IM. Molecular pathology of Lynch syndrome. J Pathol 2020; 250 (05) 518-531
    Google Scholar
  • 30 Hirama T, Tokita S, Nakatsugawa M. et al. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue. JCI Insight 2021; 6 (14) 146356
    Google Scholar
  • 31 Osterbye T, Nielsen M, Dudek NL. et al. HLA class II specificity assessed by high-density peptide microarray interactions. J Immunol 2020; 205 (01) 290-299
    Google Scholar
  • 32 Wells DK, van Buuren MM, Dang KK. et al; Tumor Neoantigen Selection Alliance. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell 2020; 183 (03) 818-834.e13
    Google Scholar
  • 33 Kalaora S, Wolf Y, Feferman T. et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov 2018; 8 (11) 1366-1375
    Google Scholar
  • 34 Hernandez-Sanchez A, Grossman M, Yeung K, Sei SS, Lipkin S, Kloor M. Vaccines for immunoprevention of DNA mismatch repair deficient cancers. J Immunother Cancer 2022; 10 (06) e004416
    Google Scholar
  • 35 Bohaumilitzky L, von Knebel Doeberitz M, Kloor M, Ahadova A. Implications of hereditary origin on the immune phenotype of mismatch repair-deficient cancers: systematic literature review. J Clin Med 2020; 9 (06) E1741
    Google Scholar
  • 36 Therkildsen C, Jensen LH, Rasmussen M, Bernstein I. An update on immune checkpoint therapy for the treatment of Lynch syndrome. Clin Exp Gastroenterol 2021; 14: 181-197
    Google Scholar
  • 37 Kloor M, Michel S, Buckowitz B. et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007; 121 (02) 454-458
    Google Scholar
  • 38 Clendenning M, Huang A, Jayasekara H. et al; investigators from the Melbourne Collaborative Cohort Study and the Australasian Colorectal Cancer Family Registry Cohort. Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas. Fam Cancer 2018; 17 (01) 91-100
    Google Scholar
  • 39 Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol 1996; 6 (12) 1695-1697
    Google Scholar
  • 40 Chang K, Taggart MW, Reyes-Uribe L. et al. Immune profiling of premalignant lesions in patients with Lynch syndrome. JAMA Oncol 2018; 4 (08) 1085-1092
    Google Scholar
  • 41 Reyes-Uribe L, Wu W, Gelincik O. et al. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa. Gut 2021; 70 (03) 555-566
    Google Scholar
  • 42 Roy HK, Turzhitsky V, Wali R. et al. Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin. Gut 2017; 66 (02) 285-292
    Google Scholar
  • 43 Giannakis M, Mu XJ, Shukla SA. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 2016; 17 (04) 1206
    Google Scholar
  • 44 Mandal R, Samstein RM, Lee KW. et al. Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. Science 2019; 364 (6439): 485-491
    Google Scholar
  • 45 Schwitalle Y, Kloor M, Eiermann S. et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134 (04) 988-997
    Google Scholar
  • 46 Ozirmak Lermi N, Gray SB, Bowen CM. et al. Comparative molecular genomic analyses of a spontaneous rhesus macaque model of mismatch repair-deficient colorectal cancer. PLoS Genet 2022; 18 (04) e1010163
    Google Scholar
  • 47 Leoni G, D'Alise AM, Cotugno G. et al. A genetic vaccine encoding shared cancer neoantigens to treat tumors with microsatellite instability. Cancer Res 2020; 80 (18) 3972-3982
    Google Scholar
  • 48 D'Alise AM, Leoni G, Cotugno G. et al. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat Commun 2019; 10 (01) 2688
    Google Scholar
  • 49 Overman M, Fakih M, Le D. 410 Phase I interim study results of Nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI). J Immunother Cancer 2021; 99 (suppl 2): A1-A1054
    Google Scholar
  • 50 Peng S, Zaretsky JM, Ng AHC. et al. Sensitive detection and analysis of neoantigen-specific T cell populations from tumors and blood. Cell Rep 2019; 28 (10) 2728-2738.e7
    Google Scholar
  • 51 Sibener LV, Fernandes RA, Kolawole EM. et al. Isolation of a structural mechanism for uncoupling T cell receptor signaling from peptide-MHC binding. Cell 2018; 174 (03) 672-687.e27
    Google Scholar
  • 52 Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer 2021; 21 (06) 360-378
    Google Scholar
  • 53 Sahin U, Derhovanessian E, Miller M. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017; 547 (7662): 222-226
    Google Scholar
  • 54 Kenter GG, Welters MJ, Valentijn AR. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361 (19) 1838-1847
    Google Scholar
  • 55 van Poelgeest MIE, Welters MJ, Vermeij R. et al. Vaccination against oncoproteins of HPV16 for noninvasive vulvar/vaginal lesions: lesion clearance is related to the strength of the T-cell response. Clin Cancer Res 2016; 22 (10) 2342-2350
    Google Scholar
  • 56 Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res 2017; 27 (01) 74-95
    Google Scholar
  • 57 Westdorp H, Fennemann FL, Weren RD. et al. Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother 2016; 65 (10) 1249-1259
    Google Scholar
  • 58 Sahin U, Oehm P, Derhovanessian E. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 2020; 585 (7823): 107-112
    Google Scholar
  • 59 Das K, Belnoue E, Rossi M. et al. A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity. Nat Commun 2021; 12 (01) 5195
    Google Scholar
  • 60 Belnoue E, Mayol JF, Carboni S. et al. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. JCI Insight 2019; 5 (11) e127305
    Google Scholar
  • 61 Belnoue E, Leystra AA, Carboni S. et al. Novel protein-based vaccine against self-antigen reduces the formation of sporadic colon adenomas in mice. Cancers (Basel) 2021; 13 (04) 845
    Google Scholar
  • 62 Yurgelun MB, Hampel H. Recent advances in Lynch syndrome: diagnosis, treatment, and cancer prevention. Am Soc Clin Oncol Educ Book 2018; 38: 101-109
    Google Scholar
  • 63 Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP. Milestones of Lynch syndrome: 1895-2015. Nat Rev Cancer 2015; 15 (03) 181-194
    Google Scholar
  • 64 Hampel H, Stephens JA, Pukkala E. et al. Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 2005; 129 (02) 415-421
    Google Scholar